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Abstract
Introduction. Pneumocystis jirovecii pneumonia (PCP) is a severe disease affecting immunocompromised patients. Diagnosis is 
difficult due to the low sensitivity of direct examination and inability to grow the pathogen in culture. Quantitative PCR in bron-
choalveolar lavage fluid (BAL) has high sensitivity, but limited specificity for distinguishing PCP from colonization.
Aim. To assess the performance of an in- house quantitative PCR to discriminate between PCP and colonization.
Methodology. This was a single- centre retrospective study including all patients with a positive PCR result for P. jirovecii in BAL 
between 2009 and 2017. Irrespective of PCR results, PCP was defined as the presence of host factors and clinical/radiological 
criteria consistent with PCP and (i) the presence of asci at direct examination of respiratory sample or (ii) anti- PCP treatment 
initiated with clinical response and absence of alternative diagnosis. Colonization was considered for cases who did not receive 
anti- PCP therapy with a favourable outcome or an alternative diagnosis. Cases who did not meet the above mentioned criteria 
were classified as ‘undetermined’.
Results. Seventy- one patients with positive P. jirovecii PCR were included (90 % non- HIV patients). Cases were classified as 
follows: 37 PCP, 22 colonization and 12 undetermined. Quantitative PCR values in BAL were significantly higher in patients with 
PCP versus colonization or undetermined (P<0.0001). The cut- off of 5×103 copies/ml was able to discriminate PCP cases from 
colonization with 97 % sensitivity, 82 % specificity, 90 % positive predictive value and 95 % negative predictive value.
Conclusions. Our quantitative PCR for P. jirovecii in BAL was reliable to distinguish PCP cases from colonization in this predomi-
nantly non- HIV population.
INTROdUCTION
Pneumocystis jirovecii is an opportunistic fungus causing 
pneumonia (PCP), a severe lung disease in patients with 
T- lymphocyte mediated immune defect [1]. Historically, 
PCP was mainly observed among patients infected by the 
human immunodeficiency virus (HIV) with low CD4 count 
[2]. However, since the introduction of highly active antiret-
roviral therapy, the prevalence of the disease among HIV- 
infected patients has decreased in developed countries while 
the proportion of cases in non- HIV immunocompromised 
patients, such as haematologic cancer patients, has increased 
[3, 4]. Mortality rates are particularly high in this latter 
patients’ population (30–60 %) [3].
PCP is a life- threatening and rapidly progressive disease, 
which should be promptly detected [3]. The diagnosis of 
PCP is difficult because patients rarely produce sputum and 
invasive procedures, such as bronchoscopy, are often required 
to get respiratory specimens. Moreover, P. jirovecii cannot be 
isolated by routine culture methods and direct examination, 
albeit specific, has low sensitivity [5]. Molecular tools based 
on PCR are becoming a cornerstone for the diagnosis of 
PCP because of their high sensitivity for P. jirovecii detection 
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[5–7]. While a negative PCR result is reliable to exclude the 
disease, a positive result could be difficult to interpret as it 
may reflect colonization instead of infection. Colonization, 
also referred to as asymptomatic carriage, corresponds to 
a situation in which the immune system is able to prevent 
the development of disease following recent exposure [8]. 
Because many pulmonary infections or non- infectious lung 
diseases may mimic PCP in non- HIV immunocompromised 
patients, the distinction between infection and colonization is 
challenging. In this study, we analysed the performance of an 
in- house quantitative P. jirovecii- specific PCR to discriminate 
PCP from colonization according to the fungal load in bron-
choalveolar lavage fluid (BAL) in a predominantly non- HIV 
population.
MeTHOdS
Study design and patients
This was a retrospective study performed at the University 
Hospital of Lausanne (Switzerland) from October 2007 
(date of introduction of PCP quantitative PCR in clinical 
routine) to December 2017. All patients with a positive P. 
jirovecii PCR in a BAL were enrolled. Clinical data were 
collected in medical records including patients’ under-
lying conditions, clinical and radiological presentation of 
pneumonia, microbiological results of BAL, therapeutic 
management of PCP and 12 week overall mortality. Two 
investigators (T.P. and A.K.) analysed the clinical data 
independently and without knowledge of the PCP PCR 
quantitative results. Irrespective of the diagnosis of PCP 
stated in medical records, cases were classified according 
to the algorithm of Fig. 1. PCP diagnosis was made in the 
presence of all the following criteria: (i) presence of at least 
one host criterion as defined in Fig. 1, (ii) clinical signs 
of respiratory infection with radiologic features consistent 
with PCP and (iii) presence of asci at direct examination by 
silver staining or introduction of antimicrobial therapy with 
anti- PCP activity with complete or partial improvement 
during the course of therapy in the absence of any alterna-
tive diagnosis. Patients were considered as ‘colonized’ if 
host criteria or clinical features of PCP were absent or if 
they did not receive anti- PCP therapy with a subsequent 
favourable outcome or a documented alternative diagnosis 
of respiratory infection or disease. All cases who did not 
fulfill the criteria of PCP or colonization were classified 
as ‘undetermined’. Discordant classification of cases was 
resolved by a consensus between F.L., T.P. and A.K.
diagnostic methods
Direct examination of P. jirovecii asci in the BAL sample 
was performed by the rapid methenamine silver- staining 
method [9]. The real- time quantitative PCR was run on 
our automated molecular diagnostic platform, as previously 
Fig. 1. Algorithm for classification of cases as PCP, colonization or undetermined. BAL, bronchoalveolar lavage fluid.
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described [10]. The PCP PCR targets the mitochondrial 
26S rDNA. The primers and protocol used in this study 
have been described elsewhere [11]. In brief, the BAL was 
centrifuged 30 min at 3000 g and the pellet was resuspended 
in remaining 2 ml of liquid. Then, 200 µl was used for 
the extraction procedure. The Kit DNA Process Control 
(Roche Molecular Systems) was used as extraction control. 
Amplification and detection were performed on an Applied 
Biosystems Quantstudio 7 Real- Time PCR System, using 
a TaqMan Fast Advanced Master Mix. In order to quan-
tify the fungal load, plasmid- positive control dilutions 
corresponding to 104, 105 and 106 copies/ml were added 
to each run. A standard dilution curve using the cycle 
threshold (Ct) value of the known range of concentrations 
allowed the quantification of the fungal load of the original 
specimen in copies/ml. Plasmid positive controls are 
Table 1. Characteristics of patients with a positive P. jirovecii PCR
PCP (N=37) Undetermined (N=12) Colonization (N=22)
Demographic data
  Female / Male 22 (59) / 15 (41) 5 (42) / 7 (58) 16 (73) / 6 (27)
  Age 59 (2–78) 64 (43–80) 61 (27–81)
Underlying diseases
  HIV infection 7 (19) 0 (0) 0 (0)
  Haematologic cancer 19 (51) 4 (33) 11 (50)
   Acute leukemia 6 (16) 0 (0) 3 (14)
   Lymphoproliferative disorder 6 (16) 3 (25) 6 (27)
   Other haematologic cancer* 7 (19) 1 (8) 2 (9)
  Solid tumour 7 (19) 5 (42) 6 (27)
  Other† 4 (11) 3 (25) 3 (14)
Immunosuppression
  Neutropenia (PMN<500/mm3) 7 (19) 0 (0) 4 (18)
  Lymphocyte CD4<200/ mm3 18 (49) 6 (50) 8 (36)
  Corticosteroids>14 days 17 (46) 9 (75) 5 (23)
  Other immunosuppressive drugs 19 (51) 7 (58) 12 (55)
Anti- PCP prophylaxis 4 (11) 0 (0) 2 (9)
Clinical/radiological features
  Hypoxemia‡ 31 (84) 9 (75) 11 (50)
  Bilateral lung lesions 35 (95) 11 (92) 20 (91)
  Ground- glass opacity (chest CT) 30 (81) 9 (75) 17 (77)
Anti- PCP therapy
  No treatment 0 (0) 0 (0) 18 (82)
  TMP- SMX 37 (100) 10 (83) 4 (18)
  Atovaquone 0 (0) 2 (17) 0 (0)
  Adjunctive corticosteroids 33 (89) 10 (83) 4 (18)
Mortality at 12 weeks 10 (27) 4 (33) 7 (32)
Values are absolute numbers (percentage) for proportions and median (range) for continuous variables.
*Other haematologic cancer: multiple myeloma, myelodysplastic syndrome or myeloproliferative disorder
†Auto- immune disorders or solid- organ transplantation.
‡Room air PaO
2
 <70 mmHg or O
2
 saturation <92 %.
PCP, P. jirovecii pneumonia; HIV, human immunodeficiency virus; PMN, polymorphonuclear neutrophils; TMP- SMX, trimethoprim- 
sulfamethoxazole.
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constructed according to our targeted PCR and produced 
by RD- Biotech, France.
PCP management
Antimicrobial therapy of PCP in our institution follows inter-
national recommendations [12]. The recommended regimen 
is trimethoprim- sulfamethoxazole (TMP- SMX) at 15 mg/kg/
day of the trimethoprim component divided in three daily 
doses (orally or intravenously) for 3 weeks. For patients with 
TMP- SMX allergy, treatment consist of atovaquone 750 mg 
twice daily for mild disease or primaquine 30 mg once daily 
and clindamycin 600–900 mg three times daily for moderate/
severe cases. Adjunctive corticosteroids are given in case of 
hypoxemia (PaO2<70 mmHg).
Statistical analyses
Quantitative PCR results were compared between the three 
groups (PCP, colonization, undetermined) using the non- 
parametric one- way ANOVA (Kruskal–Wallis) test with P- 
value considered as significant if ≤0.05. The performance of 
PCR to discriminate PCP from colonization (after exclusion 
of undetermined cases) among positive results was tested 
for different thresholds and expressed in terms of sensitivity, 
specificity, positive and negative predictive values, positive 
and negative likelihood ratios.
ethical statement
This study was approved by Swissethics (commission of the 
‘Canton de Vaud’, project number: 2018–01220) for retro-
spective use of clinical data with waiver of patients’ informed 
consent.
ReSUlTS
A total of 71 patients with a positive PCP PCR result in a 
BAL sample were included in the analysis. As shown in Fig. 1 
and 37 cases were classified as PCP according to the above- 
mentioned criteria, of which 23 (62 %) had proven infection 
on the basis of a positive direct examination for asci in BAL. In 
22 cases, PCP was excluded because of lack of host or clinical/
radiological criteria or because patients did not receive anti-
 PCP therapy or had an alternative diagnosis of respiratory 
disease. The remaining 12 cases were classified as undeter-
mined. Characteristics of patients are described for the three 
Fig. 2. Comparison of P. jirovecii quantitative PCR results between 
PCP, colonization and undetermined cases. Analysis performed by 
non- parametric one- way ANOVA (Kruskal–Wallis) test with P- value 
considered as significant if ≤0.05. **** P value <0.0001.
Table 2. Diagnostic performance of P. jirovecii PCR for the discrimination between PCP and colonization
Cut- off Sensitivity Specificity PPV NPV LR + LR - DOR
102 1 0.05 0.64 1 1.05 0 NC
5×102 1 0.23 0.69 1 1.29 0 NC
103 1 0.36 0.73 1 1.57 0 NC
5×103 0.97 0.82 0.90 0.95 5.35 0.03 162
104 0.95 0.82 0.90 0.90 5.20 0.07 78.75
5×104 0.81 0.91 0.94 0.74 8.92 0.21 42.86
105 0.76 0.95 0.97 0.70 16.65 0.25 65.33
5×105 0.62 1 1 0.61 NC 0.38 NC
106 0.51 1 1 0.55 NC 0.49 NC
5×106 0.30 1 1 0.46 NC 0.70 NC
107 0.30 1 1 0.46 NC 0.70 NC
DOR, diagnostic odds ratio; LR+, positive likelihood ratio; LR-, negative likelihood ratio; NC, not calculated; NPV, negative predictive value; PPV, 
positive predictive value.
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groups in Table 1. PCP cases were mainly non- HIV patients 
(81 %) with haematologic cancer (51 %) or solid tumours 
(19 %). All patients classified as PCP or undetermined cases 
received anti- PCP therapy (mainly with co- trimoxazole), 
while 18 % of the cases classified as colonization were treated. 
Anti- PCP therapy was already ongoing at the time of BAL in 
nine (17 %) of the treated patients (median of 1 day before 
BAL sampling, range 1–4 days).
The quantitative results of PCP PCR were significantly higher 
among PCP cases compared to both undetermined and colo-
nized cases (Fig. 2). The performance of the quantitative PCR 
to discriminate PCP from colonization for different thresh-
olds is shown in Table 2. The optimal result was obtained 
for a cut- off of 5×103 copies/ml with a sensitivity, specificity, 
positive and negative predictive value of 97, 82, 90 and 95 %, 
respectively. A 100 % sensitivity and negative predictive value 
were obtained for the cut- off of 103 copies/ml, while a cut- off 
of 5×105 copies/ml was associated with 100 % specificity and 
positive predictive value.
dISCUSSION
PCP is increasingly observed among non- HIV patients with 
different types and intensity of immunosuppression. Atypical 
clinical presentation and concomitant respiratory infec-
tions are frequent in this population making PCP diagnosis 
particularly challenging. Our analysis suggests an excellent 
ability of our quantitative PCR to discriminate PCP from 
colonization in a predominantly non- HIV population with 
a suggested cut- off of 5×103 copies/ml.
Some studies have previously assessed the performance of 
quantitative PCR cut- off values to distinguish PCP from 
colonization [13–18]. These studies (compared in Table 3) 
exhibit important heterogeneity regarding the type of popula-
tion (proportion of HIV and non- HIV patients), the type of 
sample (BAL only or including induced sputum samples), the 
PCR target (mitochondrial rRNA, dihydropteroate synthase 
gene, major surface glycoprotein), the quantification method 
of fungal load (Ct cycles or copies per ml), the definition of 
PCP cases (i.e. clinical criteria to distinguish probable cases 
from colonization), and the expression of results. Similarly to 
our analysis, most studies demonstrate significant differences 
of mean fungal loads between the categories of proven PCP, 
versus probable/possible cases and colonization. However, 
the assessment of an acceptable fungal load cut- off for distin-
guishing PCP from colonization gives various results. While 
most studies suggest a ‘grey zone’ between cut- offs providing 
Table 3. Comparative performance of quantitative P. jirovecii PCR in various studies
Study
first author, year (reference)
PCR target No. of PCP cases*
HIV / HM / others [%]
PCP classification† Results




High vs low probability <120 TFEq/ml: 100 % NPV
>1900 TFEq/ml: 100 % PPV




Proven vs IFA- negative ≤2.6 log10 copies/µl: 100 % NPV
≥4 log10 copies/µl: 100 % PPV
Matsumura, 2016 [17] Dihydropteroate synthase gene 53
9/17/74
(a) Proven vs colonization (b) 
proven/probable vs colonization
(a) 1300 copies/ml: 100 % NPV, 
79 % PPV (b) 340 copies/ml: 
44 % NPV, 91 % PPV




Proven/probable vs possible vs 
colonization
Significant differences of 
fungal load (Ct value between 
groups). Large distribution, no 
cut- off proposed.




≤3160 copies/ml: 100 % NPV
≥31 600 copies/ml: 100 % PPV




Proven/probable vs colonization 
(no possible category)
Ct 32 : 72 % sen, 75 % spe








≤103 copies/ml: 100 % NPV
5×103 copies/ml: 95 % NPV, 
90 % PPV
≥5×105 copies/ml: 100 % PPV
*Patients with PCP classified as proven or probable.
†Nomenclature for PCP classification: proven: IFA positive, probable: IFA negative / PCR positive, with defined clinical criteria for PCP diagnosis, 
possible: IFA negative / PCR positive, without fulfilling all clinical criteria for PCP diagnosis. Colonization: IFA negative / PCR positive, and no PCP 
diagnosis retained on the basis of clinical assessment.
HIV, human immunodeficiency virus; HM, haematologic malignancies; IFA, immunofluorescence assay; NPV, negative predictive value; PCP, P. 
jirovecii pneumonia; Sen, sensitivity; Spe, specificity; TFEq, trophic form equivalents.
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near 100 % positive/negative predictive values for PCP diag-
nosis, some of them found a large and overlapping distribu-
tion precluding the assessment of a reliable cut- off [15, 18]. 
Compared to previous analyses, our study has the highest 
number and proportion of haematologic cancer patients. 
Diagnosis of PCP is notoriously difficult in this population 
exposed to various types of lung injury including infectious 
causes and secondary effects of anti- cancer therapy [19].
The absence of a reliable gold standard to define PCP infection 
is an important limitation. In this study, we used stringent 
criteria to define PCP with a majority of patients (62 %) with 
proven infection on the basis of a positive direct examina-
tion and the remaining cases having responded to anti- PCP 
therapy in the absence of alternative diagnosis. Nonetheless, a 
small proportion of cases were classified as undetermined and 
were excluded from the analysis. The median fungal burden 
among these patients was close to the cut- off, suggesting a 
grey zone in the interpretation. However, our results suggest 
a reliable and relatively narrow cut- off margin with values 
<103 and >5×103 copies/ml providing 100 and 90% negative 
and positive predictive values, respectively, which seems 
appropriate to trigger therapeutic decisions. Targeted treat-
ment of PCP cases based on reliable PCR cut- offs may avoid 
unnecessary use of antimicrobial agents and their associated 
risks of toxicity or resistance.
Use of the 1,3- beta- d- glucan test in serum could be helpful 
for the assessment of PCP probability. Unfortunately, BDG 
results were not available for most cases of the present study, 
as the test was introduced in our institution only at the end of 
the study period. Another limitation consisted of the absence 
of negative controls. However, the excellent negative predic-
tive value of PCP PCR (≥99 %) has already been established 
[5]. Accordingly, we did not observe any confirmed case of 
PCP with a negative PCR result during the study period. The 
actual challenge for PCP diagnosis relies on the discrimina-
tion between PCP and colonization among patients with a 
positive PCR result, which was the specific question addressed 
in the present study. Other roles of PCP PCR, for instance as 
a screening tool in the setting of nosocomial PCP outbreaks, 
could also be investigated in the future [20, 21].
In conclusion, quantitative PCP PCR results in BAL were 
reliable to distinguish infection from colonization in this 
predominantly non- HIV population and may be used to 
guide therapeutic decisions. Thresholds should be assessed 
for each individual in- house PCR method, as different 
values may be observed according to the molecular method 
and/or patients’ population. Development of standardized 
procedures and commercial kits for quantitative PCP PCR is 
warranted. Such efforts of standardization with comparison of 
PCP PCR performance across centres and between different 
assays are ongoing [22].
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